WAM
AGRX

Warberg Asset Management’s Agile Therapeutics AGRX Stock Holding History

Warberg Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-350
Closed -$3.97K – 314
2022
Q4 		$3.97K Hold
350
– – ﹤0.01% 238
2022
Q3 		$5K Buy
+350
New +$8.61K ﹤0.01% 267

Other funds holding AGRX

LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Warberg Asset Management's AGRX Position: Q1 2023 in Review

Warberg Asset Management sold out of Agile Therapeutics (AGRX) in Q1 2023, closing a stake of 350 shares — an estimated $3.97K sold.

Warberg Asset Management first reported a position in AGRX in Q3 2022 and held it in 2 quarters. The position peaked at $5K in Q3 2022. 22 funds tracked by Wall St. Rank hold AGRX as of Q1 2023.

  • Warberg Asset Management reported no remaining Agile Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Warberg Asset Management sold 350 Agile Therapeutics shares in Q1 2023, an estimated $3.97K.
  • Warberg Asset Management first reported a position in Agile Therapeutics in Q3 2022 and held it in 2 quarters.
  • Warberg Asset Management's Agile Therapeutics position peaked at $5K in Q3 2022.
  • 22 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2023.

Based on Warberg Asset Management's 13F filing for Q1 2023, filed 15 May 2023.